Ziopharm jumps over 15% after announcing board changes
Ziopharm Oncology announced changes to the company's board earlier. Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, the date of the annual meeting of shareholders. Doug Pagan and Elan Ezickson have been nominated for election to the board's annual meeting of stockholders. Mr. Pagan and Mr. Ezickson each would bring nearly 25 years of experience in the biopharmaceutical industry to the Board, as both have held leadership positions at global pharmaceutical companies as well as emerging, clinical-stage biotech companies. "This marks the first step toward strengthening our Board, and we anticipate further announcements in the near term. We are pleased to nominate new directors like Doug and Elan as they clearly have the biopharmaceutical expertise and experience needed to guide company management in advancing Controlled IL-12 and Sleeping Beauty, two platform technologies with enormous potential to treat blood cancers and solid tumors," said Mr. Tarriff, who is Chief Executive Officer of Eagle Pharmaceuticals. "On behalf of the board and Company, we thank Sir Murray and Sen. Wyche Fowler for their many years of service and commitment to Ziopharm and its mission." Ziopharm's Board of Directors comprises seven directors, and two seats remain vacant. The company and board have begun a search and recruitment effort to fill those seats in the coming months. Shares of Ziopharm are up 15.27% in late morning trading to $2.61 per share.